Shoulder tendinopathy. Impingement syndrome of shoulder
Conditions
Interventions
Intervention 1: Control group: 1 cc equal 40 mg triamcinolone(Exir Pharmaceutical Company, made in Iran) with 2 cc of 2% lidocaine(Caspian Tamin Pharmaceutical Company, made in Iran) using 22 gauge ne
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Shoulder tendinopathy as a positive result of specific tests like Neer & Hawkins test. Visual analog scale above 4 (VAS>4). The willingness of the patients to participate in the research projects. Not having shoulder injection in the last 4 months. Age between 18 and 65 years. Not being pregnant or having the decision to become pregnant. The absence of intraarticular injection contraindications such as coagulation disorders or taking anticoagulant medicine. Having pain for more than 3 months.
Exclusion criteria
Exclusion criteria: Having any kind of mental illness. Previous history of rotator cuff tear, diabetes, coagulation disorders, fractures, rheumatologic diseases, tumors, and infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of symptoms. Timepoint: Before treatment, two weeks and three months after the end of treatment. Method of measurement: Visual Analog Scale (VAS).;The amount of physical performance. Timepoint: Before treatment, two weeks and three months after the end of treatment. Method of measurement: Quick DASH questionnaire ( Quick Disabilities of Arm, Shoulder & Hand ). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNegar Aflakian
Iran University of Medical Sciences
Outcome results
None listed